AvMed

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

<u>Directions</u>: <u>The prescribing physician must sign and clearly print name (preprinted stamps not valid)</u> on this request. All other information may be filled in by office staff; <u>fax to 1-305-671-0200</u>. No additional phone calls will be necessary if all information (<u>including phone and fax #s</u>) on this form is correct. <u>If the information provided is not complete, correct, or legible, the authorization process can be delayed.</u>

Drug Requested: (Select drug b	pelow)				
□ deferiprone (Ferriprox®) tablets	□ Ferriprox® (deferiprone) solution	□ Ferriprox® 2-day (deferiprone) tablets			
MEMBER & PRESCRIBE	R INFORMATION: Authorizat	tion may be delayed if incomplete.			
Member Name:					
Member AvMed #:	AvMed #: Date of Birth:				
Prescriber Name:					
Prescriber Signature:		Date:			
Office Contact Name:					
Phone Number:	Fax Number:				
NPI #:					
DRUG INFORMATION: A	authorization may be delayed if incon	nplete.			
Drug Name/Form/Strength:					
Dosing Schedule:	osing Schedule: Length of Therapy:				
Diagnosis:	ICD Code	ICD Code, if applicable:			
Weight (if applicable):	Date	weight obtained:			
Recommended Dosing Limit	s: Maximum 99 mg/kg/day (actual b	oody weight) in two divided doses			
	neck below all that apply. All criteriumentation, including lab results, diag				
Initial Authorization: 6 mor	nths				
☐ Member is 3 years of age or	older				
_	luding myelodysplastic syndrome or	lassemia syndrome, sickle cell disease Diamond Blackfan anemia) and has			

(Continued on next page)

	Member's serum ferritin levels are consistently >1,000 mcg/L (submit serum ferritin labs done within the last 30 days)						
	Medication will be dosed according to FDA recommendations for age, weight, serum ferritin levels an liver iron concentration						
	Member is currently established on <u>ONE</u> of the following chelator therapies for at least 90 consecutive days (verified by pharmacy paid claims): □ deferoxamine (Desferal) □ deferasirox (Exjade, Jadenu)						
	 Member continues to have ONE of the following after three (3) months of chelator therapy: □ Serum ferritin in excess of 2,500 mcg/L (submit current serum ferritin lab results) □ Liver iron concentration is >7 mg Fe/g dry weight (submit liver biopsy, MRI or other FDA-approved test results) 						
	 □ Cardiac magnetic resonance imaging (MRI T2*) is ≤ 10 ms (submit MRI T2* lab results) □ Member has had trial and intolerable life-endangering adverse event with deferasirox (Exjade, Jadenu) or deferoxamine (Desferal) (submit documentation of intolerance or adverse event) 						
	Baseline absolute neutrophil count (ANC) is $> 1.5 \times 10^9$ /L and ANC will continue to be monitored weekly while on therapy (submit current labs)						
	If requesting brand Ferriprox, documentation of trial and intolerable life-endangering adverse event with generic deferiprone must be submitted						
	Ferriprox solution may be approved for members aged 3-10 years only. If requesting Ferriprox solution for members ≥ 11 years of age, documentation that member is unable to ingest any solid dosage form must be submitted						
supp	uthorization: 12 months. Check below all that apply. All criteria must be met for approval. To ort each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be ided or request may be denied.						
	Member's ANC is $> 1.5 \times 10^9/L$ (submit current lab results)						
	Member has had a clinically significant positive response to therapy, such as decrease in liver iron concentration, decrease in serum ferritin levels, or decrease in myocardial iron accumulation (submit current LIC, serum ferritin, cardiac MRI or other test results)						
	Treatment will be withheld if serum ferritin falls consistently below 500 mcg/L						
	(Continued on next page)						

PA deferiprone (Ferri	orox)(AvMed)
(Continued from	previous page)

	l		- C 14	. Dl	v – Proprium	. D
Vienication	neino	nraviaea nv	a Specialty	Pnarmacy	v 🗕 Pranriiim	KV
Miculcation	DCIIIZ	DI U I I I I U I I I	a Specially	I mai mac	, iiobiiaii	

Not all drugs may be covered under every Plan

If a drug is non-formulary on a Plan, documentation of medical necessity will be required.

**Use of samples to initiate therapy does not meet step edit/ preauthorization criteria. **

*Previous therapies will be verified through pharmacy paid claims or submitted chart notes. *

^{*}Approved by Pharmacy and Therapeutics Committee: \(\frac{11/19/2020}{1.123/2025}\), \(\frac{123/2025}{27/2022}\), \(\frac{12/2021}{1.12/2021}\), \(\frac{12/2021}{1.12/2021}\), \(\frac{12/2022}{1.12/2022}\), \(\frac{1